BioCentury
ARTICLE | Clinical News

Apeptico reports Phase II data for pulmonary product

April 10, 2014 12:05 AM UTC

Apeptico Forschung und Entwicklung GmbH (Vienna, Austria) said orally inhaled AP301 led to earlier onset and "more pronounced activation" of pulmonary edema clearance vs. placebo in a Phase IIa trial ...